Paul Truex

Paul F. Truex is currently Executive Chairman of Anthera Pharmaceuticals and served as President and CEO between 2004-2016. He was responsible for negotiating Anthera’s multiple product licenses from Eli Lilly and Amgen and led Anthera’s successful Initial Public Offering in 2010. Prior to founding Anthera Pharmaceuticals, Mr. Truex served as a Founder, Director, President and CEO of Peninsula Pharmaceuticals where Mr. Truex raised over $81 million of institutional capital (including $21 million from a strategic partner) and negotiated both of Peninsula’s product agreements with Shionogi & Co., Ltd. and Takeda Chemical Industries. Peninsula was acquired by Johnson and Johnson in April of 2005 for $245 million in an all-cash transaction. The remaining entity, Cerexa was subsequently acquired by Forrest Laboratories for $480 million in cash.

During his career, Mr. Truex has been involved in life science transactions of over US$3 billion including Initial Public Offerings, M&A, in-licensing, out-licensing and venture financing. This includes over $300 million in venture capital investments and more than $800 million in various public equity and debt offerings including Anthera’s Initial Public Offering in 2010 and Versicor’s IPO in 2000. Prior to Peninsula, Mr. Truex was Vice President of Commercial Development for Vicuron (Acquired by Pfizer, NASDAQ: MICU) where he directed early commercial efforts for their infectious disease portfolio. Prior to joining Versicor, Mr. Truex worked at Eli Lilly and Company where he was involved and led various business development transactions including Lilly’s joint venture with Icos for the development of Cialis®, (NASDAQ: ICOS) and out-licensing of Eraxis® to Vicuron. Mr. Truex held escalating roles in marketing and sales and was involved in the launch of three different products for the primary care physician market.

Mr. Truex obtained his Masters of Business Administration in Marketing and Finance from Indiana University and a Bachelor of Arts degree in Economics from the University of Waterloo. Mr. Truex is currently a Director of CymaBay Therapeutics (NASDAQ: CBAY), Anthera Pharmaceuticals (NASDAQ: ANTH), Feldan Therapeutics (Private), Gladius Pharmaceuticals (Private) and LQT Therapeutics (Private). His past board appointments include Peninsula Pharmaceuticals, Trius Therapeutics (NASDAQ: TSRX), Eiger Pharmaceuticals (NASDAQ: EIGR), and Protagonist Therapeutics (NASDAQ: PTGX). He joined Milestone’s Board of Directors in 2012 and was Chairman of the Board from 2012 until 2016. Mr. Truex is also a member of the Indiana University West Coast Advisory Board for the Johnson Center of Entrepreneurship and Innovation.